Lupin Enters Dermatology Segment in Brazil | CORPORATE ETHOS

Lupin Enters Dermatology Segment in Brazil

By: | August 23, 2018

Aug 23: Mumbai-based pharma major Lupin Ltd on Thursday announced that it has entered into the prescription dermatology segment in Brazil with the launch of Fillerina and Recrexina under the Lupin High-End Skin Science umbrella.

Valued at $28 billion, Brazil is the world’s 6th largest pharmaceutical market, driven by growing public health expenditure and increasing household income. The dermatology segment in Brazil, worth $1.5 billion, and growing at 10% (CAGR) is one of the fastest growing segments in the country.

According to a company statement, Fillerina is a high-end anti-aging technology that incorporates a deep action innovative formulation to fill wrinkles and expression lines. Recrexina is a hair-growth formulation which stimulates natural hair growth in active and partially inactive follicles, through the use of a patented formulation of biostimulating molecules which preserve the stem cells in hair follicles.

“The launch of Lupin High-End Skin Science is a recognition of Lupin Brazil’s capabilities within the pharmaceutical market, and with the launch of Fillerina and Recrexina, we look to executing on our capabilities in this sector and address the dermatological needs of the market. The dermatology segment is a rapidly growing portion of the Brazilian pharmaceutical market. The establishment of this new division to cater to Brazil’s fast growing dermatological segment will further strengthen our presence in the region and serve to drive our future expansion plans,” said Martin Mercer – President, Latin America, Lupin.